Drug Type Trispecific T-cell engager (TriTE) |
Synonyms |
Target |
Mechanism CD3 inhibitors(T cell surface glycoprotein CD3 inhibitors), MSLN inhibitors(Mesothelin inhibitors), albumin agonists(Serum albumin agonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | CN | 15 Dec 2021 | |
Neoplasms | Preclinical | CH | 15 Dec 2021 |